ArticleScience translational medicine2022
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- In Vivo PET Imaging of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Preclinical evaluation of [Journal of molecular medicine (Berlin, Germany) · 2025Article
- Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025Article
- Neuroimaging Techniques in Huntington's Disease: A Critical Review.Movement disorders clinical practice · 2025Review
- Biodistribution and dosimetry of the PET radioligand [EJNMMI research · 2024Article
- Preclinical evaluation of the novel [European journal of nuclear medicine and molecular imaging · 2024Article
- Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.Journal of Huntington's disease · 2024Review
- Review
- Early whole-body mutant huntingtin lowering averts changes in proteins and lipids important for synapse function and white matter maintenance in the LacQ140 mouse model.Neurobiology of disease · 2023Article
- In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Early whole-body mutant huntingtin lowering averts changes in proteins and lipids important for synapse function and white matter maintenance in the LacQ140 mouse model.bioRxiv : the preprint server for biology · 2023Article
- Reduced DMovement disorders : official journal of the Movement Disorder Society · 2023Article
- A Novel Huntington's Disease Assessment Platform to Support Future Drug Discovery and Development.International journal of molecular sciences · 2022Article
- Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model.JCI insight · 2022Article
- A Positron Emission Tomography Ligand for Mutant Huntingtin Sheds Light on Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Imaging mutant huntingtin in vivo.Nature reviews. Drug discovery · 2022Article
- Selective observation of semi-rigid non-core residues in dynamically complex mutant huntingtin protein fibrils.Journal of structural biology: X · 2022Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.